Safety and Efficacy of Methylprednisolone Infiltration in Anserine Bursitis Treatment

Phase 2CompletedNCT01205477

Universidad Autonoma de Nuevo Leon58 enrolled

Overview

To investigate the safety and efficacy of methylprednisolone infiltration in anserine bursitis treatment

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

Conditions

Bursitis

Interventions

EXPERIMENTALDRUG

Infiltration of 40 mg of methylprednisolone acetate plus 1 mL of xylocaine and Diclofenac sodium 100 mg PO QD for 10 days

PLACEBODRUG

Infiltration of 1 mL of xylocaine and Diclofenac sodium 100 mg PO QD for 10 days

Eligibility

Sex: ALLMin age: 18 YearsMax age: 90 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Clinical diagnosis of anserine bursitis Exclusion Criteria: * Intraarticular pathology that reflects pain in the medial part of the knee

Locations (1)

Hospital Universitario "José Eleuterio González"

Monterrey, Nuevo León, Mexico

Outcomes

Primary Outcomes

WOMAC score

The WOMAC (Westren Ontario and McMaster Universities) index is used to assess patients with osteoarthritis of the hip or knee using 24 parameters. It can be used to monitor the course of the disease or to determine the effectiveness of anti-rheumatic medications. Pain, Stiffness and Physical functionVisual analogue scale (VAS) may be used ranging from 0 to 10.

Time frame: 4 weeks

Secondary Outcomes

VAS satisfaction

Visual Analoge Scale for satisfaction

Time frame: 4 weeks

Improvement

Percentage of improvement

Time frame: 4 weeks

SAFETY

Pain at infiltration site, ecchymosis, bleeding, paresthesias, skin infection, anaphilaxy, vasovagal reaction

Time frame: 4 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.